JP2010533498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533498A5 JP2010533498A5 JP2010517161A JP2010517161A JP2010533498A5 JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5 JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 4
- 102000048373 human GPC3 Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000010956 Glypican Human genes 0.000 claims 2
- 108050001154 Glypican Proteins 0.000 claims 2
- 108050007237 Glypican-3 Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95984507P | 2007-07-17 | 2007-07-17 | |
| US60/959,845 | 2007-07-17 | ||
| PCT/US2008/070344 WO2009012394A1 (en) | 2007-07-17 | 2008-07-17 | Monoclonal antibodies against glypican-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014137921A Division JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010533498A JP2010533498A (ja) | 2010-10-28 |
| JP2010533498A5 true JP2010533498A5 (OSRAM) | 2011-07-21 |
| JP5868593B2 JP5868593B2 (ja) | 2016-02-24 |
Family
ID=39874207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517161A Expired - Fee Related JP5868593B2 (ja) | 2007-07-17 | 2008-07-17 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
| JP2014137921A Pending JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014137921A Pending JP2014236734A (ja) | 2007-07-17 | 2014-07-03 | Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8680247B2 (OSRAM) |
| EP (1) | EP2178921B1 (OSRAM) |
| JP (2) | JP5868593B2 (OSRAM) |
| KR (2) | KR101570252B1 (OSRAM) |
| CN (1) | CN101815726B (OSRAM) |
| AU (1) | AU2008275985B2 (OSRAM) |
| CY (1) | CY1117236T1 (OSRAM) |
| DK (1) | DK2178921T3 (OSRAM) |
| ES (1) | ES2562790T3 (OSRAM) |
| HR (1) | HRP20160270T1 (OSRAM) |
| HU (1) | HUE028737T2 (OSRAM) |
| ME (1) | ME02345B (OSRAM) |
| MX (1) | MX2010000537A (OSRAM) |
| PL (1) | PL2178921T3 (OSRAM) |
| PT (1) | PT2178921E (OSRAM) |
| RS (1) | RS54624B1 (OSRAM) |
| SI (1) | SI2178921T1 (OSRAM) |
| WO (1) | WO2009012394A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| RS54624B1 (sr) * | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | Monoklonska antitela protiv glipikana-3 |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| CN101809162B (zh) * | 2007-09-28 | 2013-06-05 | 中外制药株式会社 | 血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体 |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| WO2010129904A1 (en) | 2009-05-08 | 2010-11-11 | Genentech, Inc. | Humanized anti-egfl7 antibodies and methods using same |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| US20130295613A1 (en) * | 2010-12-28 | 2013-11-07 | Chugai Seiyaku Kabushiki Kaisha | Animal cell culturing method |
| EP2998320B1 (en) * | 2011-04-19 | 2018-07-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US20140322216A1 (en) * | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| KR102159773B1 (ko) * | 2012-06-01 | 2020-09-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도 |
| CN103833852A (zh) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 |
| SI2956173T1 (sl) | 2013-02-14 | 2017-06-30 | Bristol-Myers Squibb Company | Spojine tubulizina, postopki pridobivanja in uporaba |
| CN105899515B (zh) | 2013-08-14 | 2020-01-14 | 威廉马歇莱思大学 | uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途 |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
| AU2016206808A1 (en) | 2015-01-14 | 2017-08-31 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| SG11201705646XA (en) | 2015-01-14 | 2017-08-30 | Bristol Myers Squibb Co | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN105037540A (zh) * | 2015-05-13 | 2015-11-11 | 北京比洋生物技术有限公司 | 抗磷脂酰肌醇蛋白聚糖3全人源抗体 |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| FI3298030T3 (fi) | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| WO2016208754A1 (ja) * | 2015-06-24 | 2016-12-29 | 学校法人慶應義塾 | 抗グリピカン－１－免疫抗原受容体 |
| WO2017020812A1 (zh) * | 2015-08-03 | 2017-02-09 | 科济生物医药（上海）有限公司 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
| KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
| WO2017112624A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| CN105717303A (zh) * | 2016-01-29 | 2016-06-29 | 山东康力医疗器械科技有限公司 | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| US20170326249A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| CN106084041A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 一种全人源抗GPC3的全分子IgG抗体及其应用 |
| KR20190038567A (ko) | 2016-07-26 | 2019-04-08 | 테사 테라퓨틱스 피티이. 엘티디. | 키메라 항원 수용체 |
| KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
| WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
| EP3615574A4 (en) * | 2017-04-26 | 2021-02-24 | Eureka Therapeutics, Inc. | SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE |
| IL270596B1 (en) | 2017-05-25 | 2025-09-01 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant region for use in treating cancer |
| CN109988240B (zh) * | 2017-12-29 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗gpc-3抗体及其用途 |
| EP3801629A1 (en) | 2018-05-29 | 2021-04-14 | Bristol-Myers Squibb Company | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| KR20210096167A (ko) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| HUE062089T2 (hu) | 2018-11-30 | 2023-09-28 | Rao Naik Chetana | Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások |
| US12478686B2 (en) | 2018-12-12 | 2025-11-25 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| CN113891897B (zh) * | 2019-03-21 | 2025-03-25 | 新加坡科技研究局 | 组合物 |
| IL297495A (en) | 2020-04-22 | 2022-12-01 | Dragonfly Therapeutics Inc | Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins |
| EP4146702A4 (en) * | 2020-05-07 | 2024-07-10 | Phanes Therapeutics, Inc. | Anti-tumor associated antigen antibodies and uses thereof |
| IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| JP2024515201A (ja) * | 2021-04-23 | 2024-04-05 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｇｐｃ３抗体及び使用方法 |
| CN113354737B (zh) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 |
| KR20240112375A (ko) * | 2021-08-19 | 2024-07-18 | 아디셋 테라퓨틱스, 인크. | 막 결합된 글리피칸-3의 검출 방법 |
| EP4527465A3 (en) * | 2021-10-15 | 2025-07-09 | Concept to Medicine Biotech Co., Ltd. | Anti-glypican 3 antibodies |
| EP4598586A1 (en) | 2022-10-07 | 2025-08-13 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
| KR20250096769A (ko) * | 2022-11-01 | 2025-06-27 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 글리피칸-3에 대한 이중특이성 항체 및 이의 용도 |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3426001B2 (ja) | 1993-09-16 | 2003-07-14 | 東芝機械株式会社 | ステージ内蔵型雰囲気室装置 |
| JP4312259B2 (ja) * | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP2208784B1 (en) * | 2001-06-22 | 2013-01-02 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
| WO2004067571A1 (fr) | 2003-01-30 | 2004-08-12 | Wu, Mengchao | Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci |
| CN101562197B (zh) | 2003-06-27 | 2011-08-10 | 日本电气株式会社 | 薄膜晶体管、薄膜晶体管基板及电子设备 |
| DE602005024502D1 (de) * | 2004-07-09 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
| WO2006022407A1 (ja) | 2004-08-24 | 2006-03-02 | Chugai Seiyaku Kabushiki Kaisha | 抗グリピカン３抗体を用いたアジュバント療法 |
| EP1816140A4 (en) | 2004-10-26 | 2009-09-02 | Chugai Pharmaceutical Co Ltd | ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN |
| AU2005333155B2 (en) * | 2005-03-14 | 2011-11-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
| KR101411165B1 (ko) * | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US7744800B2 (en) * | 2006-01-06 | 2010-06-29 | Molded Fiber Glass Companies | Method and apparatus for controlling the stacking height of stackable products during compression molding off stops |
| CN103172743B (zh) * | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
| RS54624B1 (sr) * | 2007-07-17 | 2016-08-31 | E. R. Squibb & Sons, L.L.C. | Monoklonska antitela protiv glipikana-3 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
-
2008
- 2008-07-17 RS RS20160157A patent/RS54624B1/sr unknown
- 2008-07-17 PT PT87962494T patent/PT2178921E/pt unknown
- 2008-07-17 HU HUE08796249A patent/HUE028737T2/en unknown
- 2008-07-17 MX MX2010000537A patent/MX2010000537A/es active IP Right Grant
- 2008-07-17 JP JP2010517161A patent/JP5868593B2/ja not_active Expired - Fee Related
- 2008-07-17 ES ES08796249.4T patent/ES2562790T3/es active Active
- 2008-07-17 AU AU2008275985A patent/AU2008275985B2/en not_active Ceased
- 2008-07-17 DK DK08796249.4T patent/DK2178921T3/en active
- 2008-07-17 SI SI200831584A patent/SI2178921T1/sl unknown
- 2008-07-17 WO PCT/US2008/070344 patent/WO2009012394A1/en not_active Ceased
- 2008-07-17 CN CN2008801031669A patent/CN101815726B/zh not_active Expired - Fee Related
- 2008-07-17 PL PL08796249T patent/PL2178921T3/pl unknown
- 2008-07-17 US US12/668,965 patent/US8680247B2/en active Active
- 2008-07-17 HR HRP20160270TT patent/HRP20160270T1/hr unknown
- 2008-07-17 ME MEP-2016-86A patent/ME02345B/me unknown
- 2008-07-17 KR KR1020107003345A patent/KR101570252B1/ko not_active Expired - Fee Related
- 2008-07-17 EP EP08796249.4A patent/EP2178921B1/en active Active
- 2008-07-17 KR KR1020157007446A patent/KR101527342B1/ko not_active Expired - Fee Related
-
2014
- 2014-02-10 US US14/176,790 patent/US9217033B2/en active Active
- 2014-07-03 JP JP2014137921A patent/JP2014236734A/ja active Pending
-
2016
- 2016-03-01 CY CY20161100174T patent/CY1117236T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533498A5 (OSRAM) | ||
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| JP7323513B2 (ja) | 抗４－１ｂｂ抗体とその作製及び使用方法 | |
| JP2014518615A5 (OSRAM) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| HRP20191483T1 (hr) | Protutijela koja reagiraju s b7-h3, njihovi imunološki aktivni fragmenti i njihova upotreba | |
| JP2012523848A5 (OSRAM) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2013545455A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| JP2014039548A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2013519364A5 (OSRAM) | ||
| JP2011526480A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2018502060A5 (OSRAM) | ||
| JP2010502183A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| JP2013545738A5 (OSRAM) | ||
| JP2010535713A5 (OSRAM) | ||
| JP2010526028A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| JP2013544756A5 (OSRAM) |